Ngā hua rapu - Isabelle Bedrosian
- E whakaatu ana i te 1 - 20 hua o te 59
- Haere ki te Whārangi Whai Ake
-
1
Contralateral prophylactic mastectomy: current perspectives mā Katharine Yao, Mark Sisco, Isabelle Bedrosian
I whakaputaina 2016Revisão -
2
-
3
The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer mā Anjana Bhardwaj, Harpreet Singh, Celestine Trinidad, Constance T. Albarracin, Kelly K. Hunt, Isabelle Bedrosian
I whakaputaina 2018Artigo -
4
-
5
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database mā Natasha M. Rueth, Heather Lin, Isabelle Bedrosian, Simona F. Shaitelman, Naoto T. Ueno, Yu Shen, Gildy V. Babiera
I whakaputaina 2014Artigo -
6
Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor–Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the N... mā Samantha M. Buszek, Heather Lin, Isabelle Bedrosian, Nina Tamirisa, Gildy V. Babiera, Yu Shen, Simona F. Shaitelman
I whakaputaina 2019Artigo -
7
-
8
Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer mā Anjana Bhardwaj, Harpreet Singh, Kimal Rajapakshe, Kazunoshin Tachibana, Nivetha Ganesan, Yinghong Pan, Preethi H. Gunaratne, Cristian Coarfa, Isabelle Bedrosian
I whakaputaina 2017Artigo -
9
Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor–Positive, Node-Positive Breast Cancer mā Nina Tamirisa, Heather Lin, Yu Shen, Simona F. Shaitelman, Meghan Karuturi, Sharon H. Giordano, Gildy V. Babiera, Isabelle Bedrosian
I whakaputaina 2020Artigo -
10
-
11
Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surg... mā Abigail S. Caudle, Isabelle Bedrosian, Denái R. Milton, Sarah M. DeSnyder, Henry M. Kuerer, Kelly K. Hunt, Elizabeth A. Mittendorf
I whakaputaina 2017Artigo -
12
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer mā Julie E. Lang, Kailash Mosalpuria, Massimo Cristofanilli, Savitri Krishnamurthy, James M. Reuben, Balraj Singh, Isabelle Bedrosian, Funda Meric‐Bernstam, Anthony Lucci
I whakaputaina 2008Artigo -
13
Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status mā Abenaa M. Brewster, Isabelle Bedrosian, Patricia A. Parker, Wenli Dong, Susan K. Peterson, Scott B. Cantor, Melissa A. Crosby, Yu Shen
I whakaputaina 2012Artigo -
14
A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients mā Isabelle Bedrosian, Gildy V. Babiera, Elizabeth A. Mittendorf, Henry M. Kuerer, Laura Pantoja, Kelly K. Hunt, Savitri Krishnamurthy, Funda Meric‐Bernstam
I whakaputaina 2010Artigo -
15
Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recognition Through an IL-12-Dependen... mā Shuwen Xu, Gary K. Koski, Mark B. Faries, Isabelle Bedrosian, Rosemarie Mick, Markus Maeurer, Martin A. Cheever, Peter A. Cohen, Brian J. Czerniecki
I whakaputaina 2003Artigo -
16
Impact of the American College of Surgeons Oncology Group Z0011 Criteria Applied to a Contemporary Patient Population mā Min Yi, Henry M. Kuerer, Elizabeth A. Mittendorf, Rosa F. Hwang, Abigail S. Caudle, Isabelle Bedrosian, Funda Meric‐Bernstam, Jamie L. Wagner, Kelly K. Hunt
I whakaputaina 2012Artigo -
17
High incidence of germline <i>BRCA</i> mutation in patients with ER low‐positive/PR low‐positive/HER‐2 <i>neu</i> negative tumors mā Rachel Sanford, Juhee Song, Angelica M. Gutierrez‐Barrera, Jessica Profato, Ashley Woodson, Jennifer K. Litton, Isabelle Bedrosian, Constance T. Albarracin, Vicente Valero, Banu K. Arun
I whakaputaina 2015Artigo -
18
Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER... mā Min Yi, Sharon H. Giordano, Funda Meric‐Bernstam, Elizabeth A. Mittendorf, Henry M. Kuerer, Rosa F. Hwang, Isabelle Bedrosian, Loren L. Rourke, Kelly K. Hunt
I whakaputaina 2010Artigo -
19
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer mā Min Yi, Savitri Krishnamurthy, Henry M. Kuerer, Funda Meric‐Bernstam, Isabelle Bedrosian, Merrick I. Ross, Frederick C. Ames, Anthony Lucci, Rosa F. Hwang, Kelly K. Hunt
I whakaputaina 2008Artigo -
20
Evaluation of a Breast Cancer Nomogram for Predicting Risk of Ipsilateral Breast Tumor Recurrences in Patients With Ductal Carcinoma in Situ After Local Excision mā Min Yi, Funda Meric‐Bernstam, Henry M. Kuerer, Elizabeth A. Mittendorf, Isabelle Bedrosian, Anthony Lucci, Rosa F. Hwang, Jaime R. Crow, Sheng Luo, Kelly K. Hunt
I whakaputaina 2012Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Cancer
Internal medicine
Breast cancer
Oncology
Surgery
Mastectomy
Biology
Surgical oncology
Ductal carcinoma
Radiology
Sentinel lymph node
Paleontology
Pathology
Stage (stratigraphy)
Gynecology
Metastasis
Biopsy
Carcinoma
Chemotherapy
Radiation therapy
Axillary Lymph Node Dissection
Lymph node
Proportional hazards model
Axilla
Cancer research
Lobular carcinoma
Lymphovascular invasion
General surgery
Multivariate analysis